Psychiatry Collaboration and Licensing Deals 2016-2023

$3,995.00

Psychiatry Collaboration and Licensing Deals | Global coverage | Deal financials | Contract documents | Deal trends | Leading dealmakers | Collaboration, licensing, development, and research deals |Comprehensive deal directory 2016 to 2023

Publication date
October 2023
Number of pages
400+
Product type
Research report
Available formats
PDF document
Report edition
4
SKU
CP2204

Psychiatry Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to the psychiatry deals entered into by the worlds leading biopharma companies.

Fully revised and updated, the report provides details of psychiatry deals from 2016 to 2023.

The report provides access to deal payment terms as announced between the parties. This data provides useful insight into the payment and other deal terms.

Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered and rights transferred – contract documents provide this insight where press releases and databases do not.

This report contains a comprehensive listing of collaboration and licensing deals announced since 2016 as recorded in the Current Agreements deals and alliances database, including financial terms where available, plus links to online copies of actual licensing contract documents as submitted to the Securities Exchange Commission by companies and their partners.

The initial chapters of this report provide an orientation of psychiatry dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an analysis of the trends in psychiatry dealmaking.

Chapter 3 covers the financial deal terms for deals signed in the psychiatry field with stage of development announced. Deals are listed and sectioned by headline value, upfront payment, milestone payment and royalty rates.

Chapter 4 provides a review of the top 25 most active biopharma companies in psychiatry dealmaking. Where the deal has an agreement contract published at the SEC a link provides online access to the contract via the Current Agreements deals and alliances database.

Chapter 5 provides a comprehensive and detailed review of psychiatry deals signed and announced since 2016 where a contract document is available. Each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.

Chapter 6 provides a comprehensive directory of psychiatry deals listed by theraeutic target.

The report also includes numerous table and figures that illustrate the trends and activities in psychiatry deal making since 2016.

In addition, a comprehensive deal directory is provided organized by company A-Z and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

 

Key benefits

Psychiatry Collaboration and Licensing Deals provides the reader with the following key benefits:

  • Understand deal trends since 2016
  • Browse psychiatry collaboration and licensing deals
  • Benchmark analysis – identify market value of transactions
  • Financials terms - upfront, milestone, royalties
  • Directory of deals by company A-Z, therapy focus and technology type
  • Leading deals by value
  • Most active dealmakers
  • Identify assets and deal terms for each transaction
  • Access contract documents - insights into deal structures
  • Due diligence - assess suitability of your proposed deal terms for partner companies
  • Save hundreds of hours of research time

 

Report scope

Psychiatry Collaboration and Licensing Deals is intended to provide the reader with an in-depth understanding of psychiatry trends and structure of deals entered into by leading biopharma companies worldwide.

Psychiatry Collaboration and Licensing Deals includes:

  • Trends in psychiatry dealmaking in the biopharma industry
  • Overview of collaboration and licensing deal structure
  • Directory of psychiatry deal records covering pharmaceutical and biotechnology
  • The leading psychiatry deals by value
  • Most active psychiatry licensing dealmakers

In Psychiatry Collaboration and Licensing Deals, the available deals are listed by:

  • Company A-Z
  • Headline value
  • Therapeutic area
  • Technology type

Each deal title links via Weblink to an online version of the actual deal record, providing easy access to each contract document where available.

Psychiatry Collaboration and Licensing Deals provides comprehensive access to available records for deals, including contract documents where available.

Analyzing contract agreements allows due diligence of:

  • What are the precise rights granted or optioned?
  • What is actually granted by the agreement to the partner company?
  • What exclusivity is granted?
  • What is the payment structure for the deal?
  • How are sales and payments audited?
  • What is the deal term?
  • How are the key terms of the agreement defined?
  • How are IPRs handled and owned?
  • Who is responsible for commercialization?
  • Who is responsible for development, supply, and manufacture?
  • How is confidentiality and publication managed?
  • How are disputes to be resolved?
  • Under what conditions can the deal be terminated?
  • What happens when there is a change of ownership?
  • What sublicensing and subcontracting provisions have been agreed?
  • Which boilerplate clauses does the company insist upon?
  • Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
  • Which jurisdiction does the company insist upon for agreement law?

Psychiatry Collaboration and Licensing Deals provides the reader with the following key benefits:

  • Understand deal trends since 2016
  • Browse psychiatry collaboration and licensing deals
  • Benchmark analysis – identify market value of transactions
  • Financials terms - upfront, milestone, royalties
  • Directory of deals by company A-Z, therapy focus and technology type
  • Leading deals by value
  • Most active dealmakers
  • Identify assets and deal terms for each transaction
  • Access contract documents - insights into deal structures
  • Due diligence - assess suitability of your proposed deal terms for partner companies
  • Save hundreds of hours of research time

Executive Summary

 

Chapter 1 – Introduction

 

Chapter 2 – Trends in psychiatry dealmaking

 

2.1. Introduction

2.2. Psychiatry partnering over the years     

2.3. Psychiatry partnering by deal type

2.4. Psychiatry partnering by industry sector

2.5. Psychiatry partnering by stage of development

2.6. Psychiatry partnering by technology type

2.7. Psychiatry partnering by therapeutic indication

 

Chapter 3 – Financial deal terms for psychiatry partnering

 

3.1. Introduction

3.2. Disclosed financials terms for psychiatry partnering

3.3. Psychiatry partnering headline values

3.4. Psychiatry deal upfront payments

3.5. Psychiatry deal milestone payments

3.6. Psychiatry royalty rates

 

Chapter 4 – Leading psychiatry deals and dealmakers

 

4.1. Introduction

4.2. Most active in psychiatry partnering

4.3. List of most active dealmakers in psychiatry    

4.4. Top psychiatry deals by value

 

Chapter 5 – Psychiatry contract document directory

                                            

5.1. Introduction

5.2. Psychiatry partnering deals where contract document available

 

Chapter 6 – Psychiatry dealmaking by therapeutic target

 

6.1. Introduction

6.2. Deals by psychiatry therapeutic target

 

Deal directory

 

Deal directory – Psychiatry deals by company A-Z 2016 to 2023

Deal directory – Psychiatry deals by technology type 2016 to 2023

 

Deal type definitions

 

About Wildwood Ventures

 

Current Partnering

Current Agreements

Recent report titles from CurrentPartnering

 

Table of figures

 

Figure 1: Psychiatry partnering since 2016

Figure 2: Psychiatry partnering by deal type since 2016

Figure 3: Psychiatry partnering by industry sector since 2016

Figure 4: Psychiatry partnering by stage of development since 2016

Figure 5: Psychiatry partnering by technology type since 2016

Figure 6: Psychiatry partnering by indication since 2016

Figure 7: Psychiatry deals with a headline value

Figure 8: Psychiatry deals with upfront payment values

Figure 9: Psychiatry deals with milestone payment

Figure 10: Psychiatry deals with royalty rates

Figure 11: Active psychiatry dealmaking activity since 2016

Figure 12: Top psychiatry deals by value since 2016

Pricing options

  • $3,995: single-user (encrypted file - one user/device)
  • $5,995: multi-user (encrypted file - up to 5 users/devices)
  • $9,995: company (unencrypted file)

Single and Multi-user license files are encrypted PDF documents. Details of how to access using Javelin3 PDF Reader will be provided at report delivery.

Company license files are not encrypted and can be accessed using a PDF Reader.

A full explanation of license type definitions can be found here.

 

Our guarantee

 

Price promise

We guarantee our prices are competitive. If you find the same report advertised at a lower price within 7 days of purchase, we will refund the difference.

 

Delivery Deadline

We guarantee that the report will be sent within the specified delivery times. In the unlikely case of a delay we may offer a partial refund as compensation. (Terms may apply)

 

Latest report

If an update is published within 30 days of your purchase, you will receive it absolutely free of charge.

 

Serious Security

We take your data and security seriously. See our privacy policy for details of how we manage your data.

All card payments are processed by Evalon.

 

Sales Support

If you have any questions about your report or are unhappy with the quality, we will do our best to resolve your query. Contact us direct.

 

Total Trust

Current Partnering is part of Wildwood Ventures Ltd., based in York, United Kingdom. We have been trading successfully online since 2009 and work with some of the most famous brands in the business. We carefully select our partners to ensure that the publications meet expectations of demanding customers.

3B Medical, 3Z, 23andMe, Abbvie, AbCellera Biologics, Accera Pharmaceuticals, Acer Therapeutics, AC Immune, Actigraph, Aculys Pharma, AcuraStem, AdAlta, Adare Pharma Solutions, Addex Therapeutics, Adimab, Advocate Health Care, Aelan Cell Technologies, AffaMed Therapeutics, Agena Bioscience, AgeneBio, AgeX Therapeutics, AiCure, Aiforia Technologies, AI Longevity, Aker BioMarine, Akili Interactive Labs, Akome Biotech, Albert Einstein College of Medicine, Alchemab, Alector, Alex Therapeutics, Alexza Pharmaceuticals, Algernon Pharmaceuticals, Alkermes, Allergan, Allied Corp, Alligator Bioscience, Alnylam Pharmaceuticals, Alpha Cognition, Altasciences, Alterity Therapeutics, Alternative Solutions, Altoida, Alto Neuroscience, Alvogen, Alzamend Neuro, Alzheimer's Association, Alzheimer's Drug Discovery Foundation, Alzheimer's Foundation of America, Alzheimer Society Research, Alzheon, AlzProtect, Alzyn, American Sleep Apnea Association, American Well, Amerigen Pharmaceuticals, Amgen, Amorsa Therapeutics, Amydis, ANANDA Scientific, Anavex Life Sciences, Ancora Bio, Andor Pharmaceuticals, Annovis Bio, Apollo Health, APRINOIA Therapeutics, Aptamer Therapeutics, AptarGroup, Aptinyx, Aquinnah Pharmaceuticals, Araclon Biotech, Arbormentis, Arcade Therapeutics, Arctic Therapeutics, Arena Pharmaceuticals, Ariana Pharma, AriBio, Arizona State University, Artelo Biosciences, Ashvattha Therapeutics, Assurex Health, Assuta Medical Centers, Astex Pharmaceuticals, AstraZeneca, ATAI Life Sciences, Atalanta Therapeutics, Athira Pharma, Attralus, Aurora Cannabis, Autifony Therapeutics, Autism Impact Fund, Autism Learning Partners, Autism Speaks, Avance Clinical, Avicanna, AXIM Biotechnologies, AxoSim, Axsome Therapeutics, Aytu BioPharma, Banner Alzheimer's Institute, Banner Health, Barrow Neurological Institute, Baszucki Brain Research Fund, Battelle Memorial Institute, Bayer, Baylor College, Baylor College of Medicine, BC Neuroimmunology, BDD Pharma, Beacon Biosignals, Beckman Coulter, BehaVR, Berg, Beth Israel Deaconess Medical Center, BetterLife Pharma, Bicycle Therapeutics, Bill and Melinda Gates Foundation, BioArctic Neuroscience, biOasis Technologies, Biocodex, Biodextris, Biogen, Biogenysis, Biohaven Pharmaceuticals, BioMed X Innovation Center, BioPep, Biopharmaceuticals Australia, Bioprojet, bioRASI, BioScript Solutions, Biotx.ai, Bird Foundation, BlackThorn Therapeutics, Blum Center for Health, BMC Medical, Boehringer Ingelheim, Bolden Therapeutics, Boston University, Boston University School of Medicine, Brain & Behavior Research Foundation, Brain Balance Achievement Centers, Brain Biomarker Solutions in Gothenburg, Brain Scientific, Braxia Scientific, Breath of Life International, Bredis Healthcare, Brigham and Women's Hospital, Bristol-Myers Squibb, Broad Institute, Buck Institute for Age Research, BullFrog AI, Burke Neurological Institute, C2N Diagnostics, C4 Therapeutics, Cadent, Cala Health, Camargo Pharmaceutical Services, Cambridge Brain Sciences, Cambridge Cognition, Camino Pharma, Canadian Armed Forces, Canadian Institutes of Health Research, Cantex Pharmaceuticals, Caprion Biosciences, Cardiff University, Carna BioSciences, Casma Therapeutics, Cassava Sciences, Catalent, CavoGene LifeSciences, CB2 Insights, CB Therapeutics, Cedar Clinical Research, CEITEC, Celgene, Cellular Dynamics International, Centene, Centessa Pharmaceuticals, Centre for Addiction and Mental Health, Cerebral, Cerevance, Cerevel Therapeutics, Certainty Health, Cerveau Technologies, Charite Universitatsmedizin Berlin, Charlotte's Web, Chattanooga Center for Neurologic Research, Children's Hospital of Philadelphia, Children's Minnesota, Cingulate, Circuit Therapeutics, Citrine Medicine, City of Hope, Clalit Health Services, Clario, Clearmind Medicine, Cleveland Clinic, Clexio, Click Therapeutics, Clinical Imaging Research Centre, Clinilabs, Closed Loop Medicine, CND Life Sciences, Cognetivity Neurosciences, Cognition Kit, Cognition Therapeutics, Cognito Therapeutics, Cognoa, CogState, Cohen Veterans Bioscience, Columbia University, Combat Stress, Commave Therapeutics, Complutense University of Madrid, Confo Therapeutics, ConSynance Therapeutics, Core One Labs, Cortechs.ai, COTA, Courtagen Life Sciences, Covar Pharmaceuticals, CRISPR Therapeutics, Crossbeta Biosciences, CTD Holdings, Curebase, Cure Network Dolby Acceleration Partners, CURE Pharmaceutical, Cybin, Cyclerion Therapeutics, Cyclo Therapeutics, Cypralis, Cytox, Dacadoo, Daiichi Sankyo, Dalhousie University, Dalriada Drug Discovery, Data Tecnica International, Deakin University, Deep Cube, Dementia Discovery Fund, Denali Therapeutics, Denovo Biopharma, Department of Defense, Department of Veterans Affairs, Develco Pharma, DiagnaMed, DiamiR, Diamond Therapeutics, Dicerna Pharmaceuticals, Digestome Therapeutics, Digital Medicine Society, DTx Pharma, DuChemBio, Durect, DyNAbind, Dystonia Medical Research Foundation, Eagle Pharmaceuticals, EarlySense, Early Signal Foundation, eemagine, EIP Pharma, Eisai, Eli Lilly, Elite Pharmaceuticals, Endo International, Endotherm, Enigma Biomedical, Enosis Therapeutics, Enterin, Enveric Biosciences, ERP Biomarker Qualification Consortium, Essential Pharmaceuticals, Essex Bio-Technology, Estee Lauder, Esteve, Eureka Eurostars, Eurofarma, European Wellness Biomedical Group, Evecxia, EverInsight Therapeutics, Eversana, Evidation Health, Evotec, Exeltis, Expansion Therapeutics, Expesicor, ExScientia, Ez Sleep Technologies, Feinstein Institute for Medical Research, Field, Filament Health, Firefly Neuroscience, Florey Institute of Neuroscience and Mental Heath, Florida Atlantic University Research, Fondazione Telethon, Forian, FORMA Therapeutics, Foundation for the National Institutes of Health (FNIH), Four H, Freespira, Frontage Clinical Services, FSD Pharma, Fujirebio Diagnostics, FusionHealth, Fuzionaire Diagnostics, GABA Therapeutics, Gaia, Gain Therapeutics, Galen, Gedeon Richter, Geisinger Health System, Genco Sciences, Genentech, General Genomics, Genetika+, GeNeuro, Geneva University Hospitals, Gentex, Georgetown University, Gilead Sciences, Ginkgo BioWorks, GL Brands, Global Alzheimer's Platform (GAP), Global Down Syndrome Foundation, GN Group, Gnosis Bioresearch, GNS Healthcare, Golden Meditech, Goldfinch Bio, Government of South Korea, Graviton Bioscience, Gray Matter, GrayMatters Health, Green Valley Pharmaceutical, GSK, GTx, Gurnet Point Capital, Hackensack Meridian Health, Hainan Sinotau Pharmaceutical, Halberd, Halucenex Life Sciences, Hangzhou Highlightll Pharmaceutical, Hapbee Technologies, Happify Health, Harmony Biosciences, Harvard College, Harvard Medical School, Harvard University, Healis Therapeutics, Hebrew University of Jerusalem, Helix, Helsinki University Central Hospital (HUCH) Comprehensive Cancer Center, Henry M. Jackson Foundation, Herophilus, Hesperos, Hitachi, HLS Therapeutics, HMNC Brain Health, Holmusk, Holobiome, Hong Kong Baptist University, Horizon Europe, Horizon Healthcare Services, Hoth Therapeutics, HP, Hummingbird Diagnostics, Hypersomnia Foundation, I-mab, IBM, Icagen, Icahn School of Medicine at Mount Sinai, Idorsia, Imanova, Imeka, ImmunoBrain Checkpoint, Impax Laboratories, Impel NeuroPharma, Impression Healthcare, Inagene Diagnostics, Incannex Healthcare, Indivior, Inexia, Infineon, Infinity BiologiX, InformedDNA, iNGENu, INmune Bio, Innosuisse, Innovate UK, Inoviem Scientific, Inscopix, InSightec, Insilico Medicine, Insitro, Institute for Functional Medicine, Institute for Molecular Medicine, Institute for Research in Biomedicine, Institute of Organic Chemistry and Biochemistry, Integrated Micro-Chromatography Systems, IntelGenx, Intellipharmaceutics, International Flavors and Fragrances, Inventia Healthcare, Inventum Genetics, inviCRO, Invo Healthcare, Ionian University, Ionis Pharmaceuticals, ISIS Innovation, IsoPlexis, Italfarmaco, Itamar Medical, iX Biopharma, IXICO, JADBio, Jaguar Health, Janssen Pharmaceuticals, Janssen Pharmaceutica NV, Janssen Research & Development, Japan Tobacco, Jazz Pharmaceuticals, JelikaLite, Jiangsu NHWA Pharmaceutical, Johns Hopkins University, Johnson & Johnson, Johnson & Johnson Consumer Companies, Johnson & Johnson Innovation, Jolly Good, Juvenile Bipolar Research Foundation, Kaneh-B, Karuna Therapeutics, Keio Gijuku University, Kelai Pharmaceuticals, KemPharm, Ketabon, Ketamine Infusions Centers of Texas, KeyWise, KGK Science, Khalpey AI Lab, Kindeva Drug Delivery, Kings College London, KinoPharma, Kogenix, KYE Pharmaceuticals, L-3 Communications, Laboratorios Bago, Lannett, La Paz Hospital, Lead Discovery Center, Leidos, Les Laboratoires Servier, LEXEO Therapeutics, Libra International, Lieber Institute, Liechti Lab, Ligand Pharmaceuticals, Lighthouse Pharmaceuticals, Limbix, Liminal VR, Linical, Litesprite, LivaNova, Living Heart Foundation, Livzon Pharmaceutical, Longeveron, Lonza, Lotus Pharmaceuticals, Lovell Government Services, LTS Lohmann Therapie-Systeme, Luca Healthcare, LUCID, Lundbeck, Luxna Biotech, Luye Pharma Group, Lyndra Therapeutics, Maastricht University, Magellan Healthcare, Magic Leap, Mallinckrodt Pharmaceuticals, Marinus Pharmaceuticals, Marubeni, Massachusetts General Hospital, Max-Planck, Mayo Clinic, McGill University, McLean Hospital, McMaster University, McQuade Center for Strategic Research and Development, MedBridge, Medibio, Medical Food Solutions Research, Medical Research Council, Medical University South Carolina, Medicines Discovery Catapult, MediPharm Labs, Mediso, Medison Pharma, Medomie Pharma, MedPharm, Meilleur Technologies, MeiraGTx, Merck and Co, Meru Health, Merz, Metabolon, Methodist Hospital Houston, Metrion Biosciences, Michael J Fox Foundation, Michigan State University, Microsoft, Milagro Pharmaceuticals, Milken Institute Center for Public Health, Mind Cure Health, MindImmune Therapeutics, Mind Medicine, Mindset Pharma, MindShift Compounds, Mindstrong Health, Mission Therapeutics, Mitacs, MitoCanada Foundation, Mitochondrial Innovation Initiative, MitoSense, MMS, Mochida Pharmaceutical, Molecular Stethoscope, Moleculera Labs, Monash University, Montefiore Health System, Montreal Heart Institute, Montreal Neurological Institute-Hospital, Morgan Stanley, Morris Animal Foundation, Mosanna Therapeutics, MPI Cognition, MSN Laboratories, MSN Pharmaceuticals, Multidisciplinary Association for Psychedelics Studies, Muses Labs, MyClearStep, Mydecine Group, MyHealios, MYnd Analytics, MYND Life Sciences, Myriad Genetics, MyVytalics, Naason Science, Nacuity Pharmaceuticals, NantHealth, Nanyang Technological University, National Disease Research Interchange, National Health Service, National Institute of Diabetes and Digestive and Kidney Diseases, National Institute of General Medical Sciences, National Institute of Health Research, National Institute of Mental Health, National Institute of Neurological Disorders and Stroke, National Institute on Aging, National Institute on Drug Abuse (NIDA), National Institutes for Quantum and Radiological Science and Technology, National Institutes of Health, National Physical Laboratory, National Research Council Canada, National University Hospital, National University of Singapore, Navidea Biopharmaceuticals, Navitor Pharmaceuticals, Neomed Institute, NeonMind Biosciences, Neos Therapeutics, NervGen Pharma, NeuCyte, Neumora Therapeutics, Neuraxpharm, Neurimmune Therapeutics, Neurim Pharmaceuticals, Neuro Assessment Systems, Neuro Bio, Neurocrine Biosciences, NeuroEM Therapeutics, NeuroFront, NeuroLex Laboratories, Neurolief, Neurolign Technologies, Neurolixis, NeuroLucent, Neuronetrix, NeuroNexus, Neuronic, NeuroRx, NeuroSense Therapeutics, NeuroSigma, Neurotrack, NeuroTracker, Neurotrope BioScience, Neurovation Labs, NeuroVision Imaging, Newly Institute, New York Presbyterian/Columbia, Nippon Chemiphar, NLS Pharmaceutics, NOCD, Noema Pharma, Northern California Institute for Research and Education, Northwestern University, Novartis, Novoron Bioscience, NRx Pharmaceuticals, Nucro Technics, Numerate, Nurosene, Nuvelution Pharma, NYU Grossman School of Medicine for Preclinical and Clinical Research, Olea Medical, Oligomerix, OnDosis, One Mind for Research, Onera Health, Ono Pharmaceutical, Optina Diagnostics, OptiNose, Optos, Orexia Therapeutics, Orexo, Orient Pharma, Orion, Oryzon, Osaka University, Ossianix, Othair Prothena, Otsuka, Ottawa Hospital Research Institute, Ovid Therapeutics, OWP Pharmaceuticals, Pain Therapeutics, Paladin Labs, Parexel, Parkinson's UK, Pasithea Therapeutics, Passage Bio, Patient-Centered Outcomes Research Institute, PaxMedica, PEAR Therapeutics, Pediatrix Therapeutics, Pennsylvania State University, Peptron, Perception Neuroscience, Pfizer, PGI Drug Discovery, Pharmaceutix, Pharmanovia, PharmaTher, Pherin Pharmaceuticals, Philips, PhoreMost, Pierre Fabre, Pixvana, PoloMar Health, PostEra, Praetego, Prasco Laboratories, Praxis, Predictmedix, Probiodrug, Proclara Biosciences, Prometheus Laboratories, ProMIS Neurosciences, Prothena, Protxx, Providence, Psilera, Psycheceutical Bioscience, Psychedelic Society Belgium, PsychoGenics, Psylo, Pulvinar Neuro, PureTech Health, Purina, Q BioMed, Quadrant Biosciences, QuantalX Neuroscience, Quanterix, Quince Therapeutics, R-Biopharm, Radboud University Nijmegen, Rainwater Charitable Foundation, RARE-X, Readout Health, Recipharm, Regenerative Medicine of Latin America, Regenxbio, Relmada Therapeutics, Remarkable Technologies, Reputable Health, Reset Pharmaceuticals, Reset Therapeutics, RespireRx Pharmaceuticals, RetiSpec, RetroBrain, Reverie Labs, Revitalist Lifestyle and Wellness, Revive Therapeutics, Ro, Roche, Roche Diagnostics, Rockefeller University, RogCon Biosciences, Rosalind Franklin University of Medical Sciences, RPRD Diagnostics, Rugen Therapeutics, Rx.Health, SABI Mind, Sage Bionetworks, Sage Therapeutics, Saladax Biomedical, Samsung Biologics, SanBio, Sanford Burnham Institute, Sanford Health, Sangamo Therapeutics, Saniona, Sanofi, Sansero Life Sciences, Santa Clara University, Sawai Pharmaceuticals, Schenker Technologies, Schrodinger, Science 37, SciNeuro Pharmaceuticals, SciSparc, Scripps Research Institute, Seelos Therapeutics, Selonterra, Sentia Medical Sciences, Sentinel Oncology, Seqster, Sequentify, Shanghai Ark Biopharmaceutical, ShangPharma, Shape Therapeutics, Shionogi, Shionogi Pharma, Shire Laboratories, Siemens Healthineers, Silo Pharma, SilverCloud Health, Sirion Biotech, Skyhawk Therapeutics, Sleep Consortium, Sleepiz, SleepScore Labs, SoftBank, SOM Biotech, Somnology, Sosei, Sosei Heptares, Sound Pharmaceuticals, Southwest College of Naturopathic Medicine & Health Sciences, Spark Biomedical, Sphere Health, SpringWorks Therapeutics, SRI International, Stalicla, Stanford University, Stanford University School of Medicine, Stem of Hope, Stratus Research Labs, Striiv, St Vincent’s Institute of Medical Research, Sumitomo Dainippon Pharma, Sumitomo Pharmaceuticals, SunGen, Sunovion Pharmaceuticals, Sun Pharma Advanced Research Company, Sunstone Therapies, SUNY Upstate Medical University, Supernus Pharmaceuticals, Swinburne University, Sylics Contract Research, Syndesi Therapeutics, Syneos Health, Synlogic, Synova Healthcare, Sysmex, T3D Therapeutics, Tabula Rasa HealthCare, Tactical Relief, Taisho Pharmaceutical, Takeda Pharmaceutical, Takeda Pharmaceuticals U.S.A, TALi, Taliaz, Target ALS Foundation, Technology University Dresden, Teijin, Terran Biosciences, Tetra Discovery Partners, Teva Pharmaceutical Industries, TFS International, The New York Stem Cell Foundation, Therapeutic Solutions International, Therapix Bio, The Regents of the University of California, TMS NeuroHealth Centers, Tokyo Metropolitan Institute of Gerontology, TONIX Pharmaceuticals, Toronto Centre for Psychedelic Science, Total Brain, Towa Pharmaceutical, Transdermal Delivery Solutions, Treventis, TrialSpark, Tridiuum, Tris Pharma, TruGenomix, Tryp Therapeutics, Tymora Analytical Operations, UCB, University Health Network, University of Arizona, University of Barcelona, University of British Columbia, University of Calgary, University of California, Davis, University of California, San Diego, University of California Berkeley, University of California Irvine, University of California Los Angeles, University of California San Francisco, University of Cambridge, University of Colorado, University of East London, University of Guelph, University of Iowa, University of Lethbridge, University of Leuven, University of Manitoba, University of Marburg, University of Maryland Baltimore, University of Miami, University of Michigan, University of Minnesota, University of Mississippi, University of Missouri, University of Nebraska, University of North Carolina, University of Oslo, University of Oxford, University of Pennsylvania, University of Pittsburgh, University of Saskatchewan, University of Southern California, University of Texas, University of Texas Health Science Center at Houston, University of Toronto, University of Utah, University of Washington, University of Wisconsin, University of Wisconsin-Madison, Uppsala University, US Air Force, US Department of Veteran Affairs, UWM Research Foundation, Vaccinex, VA Medical Center (VAMC), Vanda Pharmaceuticals, Vanderbilt University, Vect-Horus, Vektor Pharma, Veltmeyer MD, VeraSci, Veravas, Verily, Vibrent Health, ViewMind, Viome, Virginia Commonwealth University, VistaGen Therapeutics, VitalHub, Vitro Biopharma, Vividion Therapeutics, Vodafone, VoxNeuro, Voyager Therapeutics, VU Medical Center, Walgreens, Washington University in St Louis, WAVE Life Sciences, Weill Cornell Medical College, Wellcome Trust, Wellness Open Living Labs, Willow Biosciences, WinterLight Labs, Wise Therapeutics, Worldwide Clinical Trials, Wren Therapeutics, Xenon Pharmaceuticals, Xonovo, XRHealth, Yale School of Medicine, Yale University, Yamo Pharmaceuticals, Yeda Research and Development Company, Yissum Research Development, Yom Chai, York Instruments, Yumanity Therapeutics, ZAI Laboratory, Zambon, Zelira Therapeutics, Zevra Therapeutics, Zhittya Genesis Medicine, Zhongze Therapeutics, ZYUS Life Sciences

Current Partnering reports provide insight into the trends and terms of partnering deals in the global life sciences sector.

Current Partnering reports are updated every six months to ensure the user has access to the latest announcements and trends in the topic focus of the report.

Current Partnering analysts review the deal data to provide an overview and analysis of deal trends, including example deals and terms.

Current Partnering reports source deal data from our proprietary deals and alliances database, Current Agreements. The database is updated daily by our analysts with new deals as they are announced globally by the company’s party to the deal. In addition, deal records are updated with new data as it becomes available.

The data in the Current Agreements deals and alliances database is obtained from secondary sources such as publicly available industry sources including press releases, company presentations, investor presentations, company SEC filings, other company filings, company websites, conference presentations. Sources are identified to allow for user verification.

Current Partnering provides comprehensive coverage of the following partnering or deal types:
• Asset purchase
• Assignment
• Co-development
• Co-market
• Co-promotion
• Collaborative R&D
• Contract service
• CRADA
• Cross-licensing
• Development
• Distribution
• Equity purchase
• Evaluation
• Grant
• Joint venture
• Licensing
• Loan
• Manufacturing
• Marketing
• Option
• Promotion
• Research
• Royalty financing
• Settlement
• Spin out
• Sub license
• Supply
• Termination
• Warrant

Every deal record is fully categorized and includes the following data, where available:
• Industry sector
• Therapy areas
• Technology type
• Deal components
• Financial terms
• Stage of development
• Exclusivity
• Asset type
• Geographic focus
• Excluded geography
• Company press release
• SEC filing data including contract document

All financial amounts are converted to US$ using the exchange rate available on the date of deal announcement, enabling direct comparison of deal terms across international territories.

Financial data and contract documents displayed in deal records is obtained from public sources, where disclosed by the parties to the deal.